Results 21 to 30 of about 10,746,438 (360)
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.
Blood Advances, 2020 BACKGROUND Red cell transfusions remain a mainstay of therapy for patients with sickle cell disease (SCD), but pose significant clinical challenges. Guidance for specific indications and administration of transfusion, as well as screening, prevention ...
S. Chou +14 more
semanticscholar +1 more source
Hepatology, 2001 Sickle cell hepatopathy encompasses a range of hepatic pathology arising from a wide variety of insults to the liver in patients with sickle cell disease. It occurs predominantly in patients with homozygous sickle cell anemia, and to a lesser extent in patients with sickle cell trait, Hb SC disease and Hb S b thalassemia.
S, Banerjee, C, Owen, S, Chopra
openaire +2 more sources
Identification of the Rare, Four Repeat Allele of IL-4 Intron-3 VNTR Polymorphism in Indian Populations [PDF]
Iranian Journal of Immunology, 2016 Background: Cytokines are cell signaling molecules which upon release by cells facilitate the recruitment of immune-modulatory cells towards the sites of inflammation. Genetic variations in cytokine genes are shown to regulate their production and affect
Henu Kumar Verma +4 more
doaj
Mediterranean Journal of Hematology and Infectious Diseases, 2009 Hematopoietic stem cell transplantation (HSCT) still remains the only definitive cure currently available for patients with thalassemia and sickle cell anemia.
Marco Marziali +3 more
doaj +1 more source
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.
New England Journal of Medicine, 2020 BACKGROUND Sickle cell disease is characterized by hemolytic anemia, pain, and progressive organ damage. A high level of erythrocyte fetal hemoglobin (HbF) comprising α- and γ-globins may ameliorate these manifestations by mitigating sickle hemoglobin ...
Erica B Esrick +24 more
semanticscholar +1 more source
International Journal of Neonatal Screening, 2019 This discussion paper has been written to show the unique contribution and added value that Patient Organisations can give to the development and improvement of newborn screening programmes for sickle cell disorder (SCD) and other haemoglobinopathies in ...
John James, Elizabeth Dormandy
doaj +1 more source
Hemato, 2022 Hematological and biochemical reference values in sickle cell disease (SCD) are crucial for patient management and the evaluation of interventions. This study was conducted at Muhimbili National Hospital (MNH) in Dar es Salaam, Tanzania, to establish ...
Anna Daniel Fome +9 more
doaj +1 more source
Electronics, 2020 Sickle cell anemia, which is also called sickle cell disease (SCD), is a hematological disorder that causes occlusion in blood vessels, leading to hurtful episodes and even death.
Laith Alzubaidi +4 more
semanticscholar +1 more source
Case Reports in Hematology, 2023 Fat embolization syndrome (FES) is often seen as a complication of fractures and has been known to cause respiratory failure, rashes of the skin, thrombocytopenia, and neurological damage.
Ram Prakash Thirugnanasambandam +4 more
doaj +1 more source
Frontiers in Genetics, 2022 Background: Sickle cell disease (SCD) is a global public health priority due to its high morbidity and mortality. In Tanzania, SCD accounts for 7% of under-five mortality. Cost-effective interventions such as early diagnosis and linkage to care have been
Agnes Jonathan +14 more
doaj +1 more source